Lynozyfic™ (linvoseltamab-gcpt) – New drug approval
July 2, 2025 - Regeneron announced the FDA approval of Lynozyfic (linvoseltamab-gcpt), for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.